BioCryst IV flu antiviral peramivir under FDA review
This article was originally published in Scrip
Executive Summary
Shares of BioCryst Pharmaceuticals jumped 14.8% on 25 February on the news the FDA has accepted for review the company's new drug application (NDA) for its intravenous antiviral peramivir as a treatment for acute uncomplicated influenza in adults.